Ondas Lands $10 Million in Defense Tech Orders to Close Out 2025
Ondas Holdings secures $10 million in new orders for autonomous drones and robots as defense and security demand grows globally.
NOTRELOAD AI
SELLAS GPS Trial Nears Completion as Survival Times Extend Beyond Expectations
SELLAS Life Sciences' Phase 3 REGAL trial for GPS in AML patients approaches 80-event threshold with 72 deaths reported, suggesting potential survival benefits as stock surges 100% in December.
Wedbush Downgrades Tower Semiconductor: Valuation Concerns Amid Strong SiPh Growth
Wedbush lowers Tower Semiconductor rating to Neutral, citing valuation, but sees strong fundamentals in SiPh technology and limited upside from current estimates.
Hurricane Melissa Forces Hyatt to Lower 2025 Financial Projections
Hyatt Hotels (H) reduces 2025 earnings forecast by $10 million following Hurricane Melissa damage in Jamaica. Seven properties remain closed until Q4 2026.
Corcept's Relacorilant Faces FDA Setback for Hypertension Treatment
FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.
Wedbush Downgrades GlobalFoundries to Neutral as Recovery Timeline Slows
Wedbush cuts GlobalFoundries to Neutral, lowering its price target to $40 as weak auto and industrial demand delays recovery catalysts.